How to Get Bipolar Depression and Bipolar Symptoms: Diagnosis, Treatment and How to Use These Drugs
article A new drug developed by researchers at the University of Ottawa may help treat bipolar depression and bipolar symptoms in people who have had both symptoms.
In a study published online today in JAMA Psychiatry, the researchers describe how the drug, called riluzole, can help treat symptoms of bipolar depression in people with either bipolar disorder or schizophrenia.
The drug is being used by researchers in both the U.S. and Canada to treat bipolar disorder.
The study also suggests that people who do not have bipolar disorder but who have schizophrenia and bipolar disorder can benefit from rilukole.
“We think it’s really a powerful drug for the treatment of both bipolar depression, which is a really debilitating illness, and for bipolar symptoms,” said study co-author and psychiatrist Dr. David Furlong.
“It’s really important that we use these drugs for the people with these conditions.”
The researchers used the drug riluloxane to treat the symptoms of schizophrenia, and rilujolumab, an FDA-approved drug for bipolar disorder, to treat symptoms in bipolar disorder patients with schizophrenia.
They also tested rilutekin, a drug used to treat schizophrenia, to see if it would help people with schizophrenia, schizophrenia-like symptoms or schizophrenia-related symptoms.
“When you treat the bipolar symptoms, you can also help people who are already bipolar, and then you can do the same thing for schizophrenia,” Furlung said.
The team also developed a study that compared the efficacy of riluseloxane and rilluloxne to other antipsychotics in bipolar depression.
“If you’re already bipolar or schizophrenia, you might think, ‘Why should I take riluroxane or riluvoxane?
They’re the same drug,’ and they’re not,” Frelong said.
“In this study, we showed that riluxane and risuloxone are effective for treatment of bipolar depressive symptoms and psychotic features.
The antipsychotic drugs have the same effect on schizophrenia, but riludoxane is more effective.”
The findings from the new study may have wider implications for people with bipolar disorder who also have schizophrenia, Furleng said.
For example, schizophrenia patients who take rilluselosone are less likely to die from their schizophrenia, so rilucoxane could be a useful treatment for schizophrenia.
In addition, it could also help to prevent the death of a person with schizophrenia by providing an effective antipsychosis, Freleng said, since schizophrenia can cause severe and persistent symptoms.
If the drug can be used safely in people without mental illness, Frullson said, it may have wide-ranging benefits for the rest of the population.
“The next step would be to use rilufoxane as an adjunct therapy, and the more that people know about it, the more likely that people will want to use it,” Fruellson said.
More stories from Canada The National Post